Literature DB >> 12798649

Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague.

Helen S Garmory1, Kate F Griffin, Katherine A Brown, Richard W Titball.   

Abstract

Bubonic and pneumonic plague are caused by the bacterium Yersinia pestis. The V antigen of Y. pestis is a protective antigen against plague. In this study, an aroA attenuated strain of Salmonella enterica serovar Typhimurium (SL3261) has been used to deliver the Y. pestis V antigen as a candidate oral plague vaccine. SL3261 was transformed with the expression plasmid pTrc-LcrV, containing the lcrV gene encoding V antigen. Immunoblot analysis showed V antigen expression in SL3261 in vitro and intragastric immunisation of mice with the recombinant Salmonella resulted in the induction of V antigen-specific serum antibody responses and afforded protection against Y. pestis challenge. However, the antibody responses induced by the recombinant Salmonella did not correlate with the protection afforded, indicating that immune responses other than antibody may play a role in the protection afforded against plague by this candidate vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798649     DOI: 10.1016/s0264-410x(03)00112-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.

Authors:  Silvia I Cazorla; Pablo D Becker; Fernanda M Frank; Thomas Ebensen; María J Sartori; Ricardo S Corral; Emilio L Malchiodi; Carlos A Guzmán
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

Review 2.  Developing live vaccines against plague.

Authors:  Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2011-09-14       Impact factor: 0.968

3.  Development of in vitro correlate assays of immunity to infection with Yersinia pestis.

Authors:  J Bashaw; S Norris; S Weeks; S Trevino; J J Adamovicz; S Welkos
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

4.  An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth.

Authors:  Yan Chen; Xin Liu; Cong Guo Jin; Yong Chun Zhou; Roya Navab; Kristine Raaby Jakobsen; Xiao Qun Chen; Jia Li; Ting Ting Li; Lu Luo; Xi Cai Wang
Journal:  Tumour Biol       Date:  2015-09-16

5.  Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.

Authors:  Anna N Honko; Nammalwar Sriranganathan; Cynthia J Lees; Steven B Mizel
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

6.  TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.

Authors:  Jr-Shiuan Lin; Steven Park; Jeffrey J Adamovicz; Jim Hill; James B Bliska; Christopher K Cote; David S Perlin; Kei Amemiya; Stephen T Smiley
Journal:  Vaccine       Date:  2010-09-15       Impact factor: 3.641

7.  Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization.

Authors:  Hui Zhang; Liu Liu; Ke Wen; Jinlin Huang; Shizhong Geng; Junsong Shen; Zhiming Pan; Xinan Jiao
Journal:  Cell Mol Immunol       Date:  2011-08-15       Impact factor: 11.530

8.  Evaluation of YadC protein delivered by live attenuated Salmonella as a vaccine against plague.

Authors:  Wei Sun; Joseph Olinzock; Shifeng Wang; Shilpa Sanapala; Roy Curtiss
Journal:  Pathog Dis       Date:  2013-09-10       Impact factor: 3.166

9.  Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.

Authors:  Philip A Arlen; Michael Singleton; Jeffrey J Adamovicz; Yi Ding; Abdolreza Davoodi-Semiromi; Henry Daniell
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 10.  Immune defense against pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.